P3, N=332, Recruiting, Nantes University Hospital | Not yet recruiting --> Recruiting | Initiation date: Feb 2024 --> Dec 2024

P2, N=60, Enrolling by invitation, Cedars-Sinai Medical Center | Trial primary completion date: Oct 2024 --> Oct 2025

P=N/A, N=50, Recruiting, The University of Hong Kong | Unknown status --> Recruiting | Trial completion date: Jun 2021 --> Dec 2028 | Trial primary completion date: Mar 2021 --> Dec 2028

Of these drugs, IL-23 inhibitors (aOR 2.47 95% CI 1.17-5.18), Janus kinase inhibitors (aOR 2.32 95% CI 1.09-4.92), and azathioprine (aOR 2.16 95% CI 1.18-3.96) were the only classes that significantly contributed to increased NMSC risk in psoriasis patients.Psoriasis is independently associated with NMSC...NMSC is treatable and high-risk patients may benefit from increased surveillance or preventative counseling. Further prospective studies that assess medication dose and length of exposure should validate our findings.

P3, N=117, Terminated, Oculis | Trial completion date: Dec 2024 --> May 2024 | Recruiting --> Terminated; Sponsor decision to close study due to third-party administrative error preventing analysis of trial results. There was no issue in terms of quality of the investigational product, and no safety risk to any study subject.

Seven months later, the patient underwent follow-up EGD, and the disappearance of lymphoma cells was confirmed histopathologically by biopsy. Repeated and detailed endoscopic examination should be considered in an immunosuppressed patient with treatment-resistant gastric or duodenal ulcers.

P2, N=30, Recruiting, Chinese PLA General Hospital | Initiation date: Dec 2019 --> Dec 2020 | Trial primary completion date: Aug 2024 --> Dec 2024

The core-shell nano-emulsion, incorporating a repurposed drug, could disrupt the β-catenin connections in the Wnt/β-catenin pathway. In conclusion, MQ/GNE-GNP could be a promising core-shell nano emulsion for the effective treatment of liver cancer by targeting the Wnt/β-catenin pathway.

P=N/A, N=75, Recruiting, Mario Negri Institute for Pharmacological Research | Not yet recruiting --> Recruiting

P4, N=112, Not yet recruiting, prof. Tomas Reischig, MD, PhD - Faculty of Medicine in Pilsen, Charles University, and Teaching Hospital

P=N/A, N=39, Recruiting, Peking University People's Hospital | Not yet recruiting --> Recruiting | Initiation date: Jan 2025 --> Jan 2024

In turn, the results indicate that the anti-asthmatic action induced by the studied agents is not mediated by the generation of forkhead box protein 3-expressing CD4+ regulatory T cells. Clinical implication of the the results suggest that MMF and TFB may exert anti-asthmatic action, and thus they may be considered therapeutic options for the treatment of allergic asthma cases resistant to conventional/existing treatment.

P1, N=68, Recruiting, University of Michigan Rogel Cancer Center | Trial completion date: Oct 2027 --> Feb 2028 | Trial primary completion date: Oct 2024 --> Feb 2025

We hypothesize that this reaction was triggered by azathioprine dose reduction. Dose modification of long-term immunosuppressive medications in patients with a transplantation history who later develop SCCs warrants further investigation.

The patient showed a limited response to a combined therapy regimen of prednisone, iguratimod, and tacrolimus. This report also discusses the potential role of inflammatory cytokines in the pathophysiology of CADM and RP-ILD. Further research is required to confirm these results and investigate the application of MMF in maintenance therapy for CADM-associated RP-ILD.

P4, N=80, Not yet recruiting, The Third Affiliated Hospital, Sun Yat-sen University; The Third Affiliated Hospital, Sun Yat-sen University

We recently demonstrated that INO can be added safely to a non-myeloablative conditioning of bendamustine, fludarabine, and rituximab in patients with indolent lymphoid malignancies who required an allogeneic hematopoietic transplantation (HCT) (Am J Hematol 2024)...Patients who received transplants from MUDs received an additional dose of methotrexate 5 mg/m2 on day +11 and 1 mg/kg of rabbit anti-thymocyte globulin IV on days -1 and -2 before HCT...The patient who was in CR2 at transplant had Ph+ ALL and was maintained on ponatinib after HCT. Key prior therapies in ALL patients included blinatumomab (n=5) and INO (n=5)...The survival outcomes are encouraging and need to be validated in a larger number of patients. Currently, post-transplant cyclophosphamide has been implemented to lessen the risk of GVHD.

Treatment with prednisolone and mycophenolate mofetil was initiated, resulting in subsequent clinical improvement. In conclusion, this case of anti-MDA5 positive CADM underscores the diverse range of clinical and radiological findings and the diagnostic challenges they pose. It highlights the importance of anti-MDA5 antibodies as a valuable diagnostic and prognostic tool, given their association with an elevated risk of developing interstitial lung disease (ILD), which may follow a rapidly progressive course and can be further complicated by pneumomediastinum.

P3, N=350, Recruiting, Oculis | Trial completion date: Dec 2025 --> Jun 2026 | Initiation date: Dec 2023 --> Mar 2024 | Trial primary completion date: Dec 2025 --> Jun 2026

P2, N=300, Recruiting, Assistance Publique - Hôpitaux de Paris | Trial completion date: Apr 2025 --> Oct 2025 | Trial primary completion date: Feb 2024 --> Apr 2025

P2/3, N=38, Completed, Columbia University | Unknown status --> Completed

P1, N=23, Active, not recruiting, Ohio State University Comprehensive Cancer Center | Recruiting --> Active, not recruiting | N=10 --> 23 | Trial completion date: Dec 2022 --> Dec 2024 | Trial primary completion date: Dec 2022 --> Dec 2024

P4, N=240, Active, not recruiting, Mayo Clinic | Trial completion date: Jul 2024 --> Jul 2025 | Trial primary completion date: Jul 2024 --> Jul 2025

Azathioprine is metabolized into thioguanine nucleotides (TGNs) which are its major active metabolites. Our findings indicate a prevalence of NUDT15 variants in AIBD patients that is similar to the prevalences of previous studies on patients with other diseases. These results emphasize the importance of screening for NUDT15 variants prior to initiating azathioprine treatment in Japanese patients with AIBDs.

P2/3, N=108, Not yet recruiting, Institute of Liver and Biliary Sciences, India

P4, N=350, Not yet recruiting, Mayo Clinic | Initiation date: Oct 2024 --> Jan 2025

P2, N=52, Not yet recruiting, Assistance Publique - Hôpitaux de Paris

Molecular studies, including western blot analysis and immunocytochemistry, revealed that Isotelekin reduced the expression of iNOS (Inducible nitric oxide synthase), COX-2 (Cyclo-Oxygenase 2), and p-IkBα (Phospho I-kappa-B-alpha), and significantly inhibited the nuclear translocation of NF-κB/p65. Based on these results, Isotelekin at 10 µm in in vitro and at 30 mg kg-1 in in vivo demonstrated strong anti-inflammatory and immunosuppressive therapeutic potential.

P2, N=170, Active, not recruiting, St. Jude Children's Research Hospital | Recruiting --> Active, not recruiting | N=52 --> 170

P1/2, N=24, Completed, National Institute of Allergy and Infectious Diseases (NIAID) | N=10 --> 24

P2, N=177, Active, not recruiting, Institut Paoli-Calmettes | Unknown status --> Active, not recruiting | Trial completion date: Dec 2018 --> Jul 2026 | Trial primary completion date: Dec 2018 --> Jul 2026

P2, N=200, Recruiting, AHS Cancer Control Alberta | Trial completion date: Sep 2025 --> Sep 2026 | Trial primary completion date: Sep 2025 --> Sep 2026

P2, N=101, Active, not recruiting, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Recruiting --> Active, not recruiting

The majority of Greek patients with IBD have a favorable pregnancy outcome. Active inflammation during gestation and a diagnosis of ulcerative colitis are negatively associated with pregnancy outcomes.

P=N/A, N=5, Active, not recruiting, Pfizer | N=100 --> 5 | Trial completion date: Feb 2026 --> Jan 2027 | Trial primary completion date: Feb 2026 --> Jan 2027

P1/2, N=0, Withdrawn, Selecta Biosciences, Inc. | Suspended --> Withdrawn

In selected patients with permanently unresectable colorectal liver metastases, liver transplantation plus chemotherapy with organ allocation priority significantly improved survival versus chemotherapy alone. These results support the validation of liver transplantation as a new standard option for patients with permanently unresectable liver-only metastases.

Despite great therapeutic advances in the field of biologics, small synthetic molecules such as thiopurines, including azathioprine, mercaptopurine, and thioguanine, remain an important therapeutic pillar in the treatment of inflammatory bowel disease, other autoimmune disorders, and cancer. In addition, the article takes a critical look at emerging research in the field of thiopurine pharmaco genomics featuring novel genetic markers and technological developments in genetic testing. Finally, the potential of integrated approaches that combine genetic, meta bolic, and clinical factors to further individualize thiopurine therapy is highlighted.

Prednisone was reinitiated at 1 mg/kg, and she was started on mycophenolate mofetil (MMF). Despite this, a rapid response to corticosteroids was observed including reversal of profound transfusion dependence, normalization of hemoglobin, and reversal of biochemical evidence of hepatic inflammation. A shared pathogenesis of autoimmune fibrosis in both the bone marrow and liver is speculative but suggested by the temporal association in this case.

In AAV patients, the use of cyclophosphamide and azathioprine (AZA) alone has a clear carcinogenic risk, with frequent use of CYC potentially posing a high risk for lung cancer. Although TNF inhibitors (TNFi) combined with CYC have carcinogenic risks, there is insufficient evidence to link them directly to an increased risk of lung cancer. For patients at high risk for lung cancer, the judicious use of immunosuppressants, timely computed tomography (CT), and lung cancer screening can reduce the risk of lung cancer in AAV patients.

P4, N=204, Completed, Chinese PLA General Hospital | Recruiting --> Completed

P3, N=84, Completed, University Medical Center Groningen | Unknown status --> Completed